Evaluation of Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction Treated With Warfarin or Reduced Dose Rivaroxaban
Latest Information Update: 31 Dec 2019
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Stroke
- Focus Adverse reactions
- Acronyms CALLIPER
- Sponsors Bayer
- 09 May 2019 Status changed from active, no longer recruiting to completed.
- 17 Jan 2019 Planned End Date changed from 31 Dec 2018 to 30 Apr 2019.
- 17 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 30 Apr 2019.